HK StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Hillhouse Capital Related

513.048

-0.450-0.09%

Number of Gainers:28

Number of Losers:19

Number of Flat:8

PE:- -

High:516.134

Open:513.498

Low:507.279

Close:513.498

Loading ...

Zhaoke Ophthalmology Ltd - FDA Clearance of Ind Application for Csa Ophthalmic Gel

THOMSON REUTERS

Genscript Biotech's Myeloma Drug Shows Progression-Free Survival in One-Third of Patients During Study

MT Newswires Live

Innovent's Phase 1 Trial for Lung Cancer Drug Shows Manageable Safety, Long-Term Survival Benefits; Shares Surge 14%

MT Newswires Live

BUZZ-Hansoh hits near 4-year peak as its cancer drug gets UK marketing approval

Hansoh Pharmaceutical's Aumolertinib Mesilate Tablets Approved by UK MHRA for Marketing

Hansoh Pharmaceutical - Aumolertinib Mesilate Tablets Was Approved by Mhra for Marketing

THOMSON REUTERS

Legend Biotech Announces Promising Phase 1 Results for LB2102 CAR-T Therapy in Lung Cancer Patients

HBM Holdings Ltd. Files Next Day Disclosure Return to HKEX Announcing Repurchase of 100,000 Shares at HKD 9.0667 Each

JW Cayman Therapeutics Co. Ltd. Held Extraordinary General Meeting

BRIEF-Xinyi Energy Announces Proposed PRC Listing Of Selected Solar Farm Projects

Xinyi Energy - Proposed PRC Listing of Selected Solar Farm Projects by Way of Solar Farm Infrastructure REIT

THOMSON REUTERS

Xinyi Energy - Application Materials for Proposed PRC Listing Have Been Submitted to Ndrc

THOMSON REUTERS

Youzan Technology Ltd. Buys Back 2 Million Units for HKD 180,000

Innovent Biologics Announces Promising Phase 1/2 Results for IBI354 in Advanced Solid Tumors at 2025 ASCO Meeting

Frontage Holdings Corporation Expands with New State-of-the-Art CRDMO Facility in Exton, PA

Haidilao founder, Ray Dalio, Forrest Li’s wife among ultra-rich splurging on 8-figure Singapore properties

MicroPort CardioFlow Medtech Unit to Acquire Balance Stake in Medical Device Firm

MT Newswires Live

Zylox-Tonbridge Announces Share Repurchase of 80,000 Shares for HKD 1,492,250 in HKEX Disclosure Filing

Hansoh Pharmaceutical Signs $80 Million License Agreement with Regeneron for Drug Development

Hansoh Pharmaceutical - Licensors Will Receive an Upfront Payment of US$80 Mln and Be Eligible to Receive up to US$1.93 Bln in Milestone Payments

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/BK1583/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK1583","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1583\",,,,,undefined,":{"symbol":"BK1583","market":"HK","secType":"PLATE","nameCN":"Hillhouse Capital Related","latestPrice":513.04846,"timestamp":1749197315346,"preClose":513.49805,"halted":0,"volume":787771556,"delay":0,"changeRate":-0.000876,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Market Closed","change":-0.449585,"latestTime":"06-06 16:00:00","open":513.49805,"high":516.1344,"low":507.27917,"amount":15627538503,"amplitude":0.017245,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1749432600000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1749173400000,1749182400000],[1749186000000,1749196800000]],"pbRate":2.369138,"peRate":22.094004,"turnoverRate":0.005389,"increases":30,"decrements":20,"flats":4,"marketCap":2901322639680,"floatMarketCap":2286727975232},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1583\",,,,,undefined,":{"symbol":"BK1583","high":516.1344,"amplitude":0.017245,"preClose":513.49805,"low":507.27917,"pbRate":"2.369138","latestPrice":513.04846,"volume":787771556,"delay":0,"open":513.49805,"prevYearClose":446.93042,"prevWeekClose":496.286,"prevMonthClose":496.286,"prevQuarterClose":505.776,"fiveDayClose":496.286,"twentyDayClose":480.539,"sixtyDayClose":530.16,"secType":"PLATE","market":"HK","turnoverRate":0.005389,"peRate":22.094004,"marketCap":2901322639680,"floatMarketCap":2286727975232,"timestamp":1749197315346,"nameCN":"Hillhouse Capital Related"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1583\",,,,undefined,":{"bkCode":"BK1583","up":28,"down":19,"flat":8},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1583\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2540405408","title":"Zhaoke Ophthalmology Ltd - FDA Clearance of Ind Application for Csa Ophthalmic Gel","url":"https://stock-news.laohu8.com/highlight/detail?id=2540405408","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540405408?lang=en_us&edition=fundamental","pubTime":"2025-06-04 18:06","pubTimestamp":1749031586,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250604:nFWN3S70EH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1583","BK1191","BK1587","06622","BK1574"],"gpt_icon":0},{"id":"2540051652","title":"Genscript Biotech's Myeloma Drug Shows Progression-Free Survival in One-Third of Patients During Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2540051652","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540051652?lang=en_us&edition=fundamental","pubTime":"2025-06-04 17:46","pubTimestamp":1749030408,"startTime":"0","endTime":"0","summary":"Genscript Biotech (HKG:1548) subsidiary Legend Biotech said one-third of patients with relapsed/refractory multiple myeloma in its ciltacabtagene autoleucel study showed progression-free survival for ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1576","HK0000320264.USD","HK0000306701.USD","HK0000320223.HKD","BK1141","BK1583","01548","HK0000306685.HKD"],"gpt_icon":0},{"id":"2540799031","title":"Innovent's Phase 1 Trial for Lung Cancer Drug Shows Manageable Safety, Long-Term Survival Benefits; Shares Surge 14%","url":"https://stock-news.laohu8.com/highlight/detail?id=2540799031","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540799031?lang=en_us&edition=fundamental","pubTime":"2025-06-04 15:10","pubTimestamp":1749021006,"startTime":"0","endTime":"0","summary":"Innovent Biologics'  IBI363 medication for immunotherapy-resistant non-small cell lung cancer and wild-type lung adenocarcinoma showed a manageable safety profile, efficacy, and long-term survival benefits during its phase 1 study.The drug company presented the findings during the 2025 American Society of Clinical Oncology Conference, according to a Wednesday news release.IBI363 also showed breakthrough therapeutic potential from tumor response to long-term survival benefits for patients with immuno-resistant squamous non-small cell lung cancer, and wild-type lung adenocarcinoma, especially with those who smoked.Shares surged 14% during Wednesday's afternoon trading.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU1969619763.USD","BK1161","LU2488822045.USD","BK1583","BK1589","LU2328871848.SGD","01801"],"gpt_icon":0},{"id":"2540350010","title":"BUZZ-Hansoh hits near 4-year peak as its cancer drug gets UK marketing approval","url":"https://stock-news.laohu8.com/highlight/detail?id=2540350010","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540350010?lang=en_us&edition=fundamental","pubTime":"2025-06-04 13:49","pubTimestamp":1749016175,"startTime":"0","endTime":"0","summary":"BUZZ-Hansoh hits near 4-year peak as its cancer drug gets UK marketing approval ** Shares of Hansoh Pharmaceutical Group 3692.HK rise 3.8% to HK$27.5, their highest levels since August 2021** Stock marks biggest intraday pct gain since May 20, and on track for a third straight session of rise, if current trend holds ** Stock is fifth-biggest pct gainer on the Hang Seng Commerce & Industry Index .HSNC, which climbs 0.8% ** Hansoh says its innovative drug Aumolertinib Mesilate Tablets for lung cancer has been approved by the Medicines and Healthcare Products Regulatory Agency  in the UK for marketing** The Hang Seng Biotech Index .HSHKBIO rises 3.1% and the Hang Seng Index .HSI adds 0.5%** YTD, stock up 56.8%  ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250604:nL2N3S704L:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","03692","BK1589","BK1583"],"gpt_icon":0},{"id":"2540038640","title":"Hansoh Pharmaceutical's Aumolertinib Mesilate Tablets Approved by UK MHRA for Marketing","url":"https://stock-news.laohu8.com/highlight/detail?id=2540038640","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540038640?lang=en_us&edition=fundamental","pubTime":"2025-06-04 12:08","pubTimestamp":1749010133,"startTime":"0","endTime":"0","summary":"Hansoh Pharmaceutical Group Co. Ltd. has announced that its innovative drug, Aumolertinib Mesilate Tablets , has been approved by the Medicines and Healthcare Products Regulatory Agency  in the United Kingdom for marketing. Aumseqa is indicated for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer  with activating epidermal growth factor receptor  mutations, and for the treatment of adult patients with locally advanced or metastatic EGFR T790M mutation-positive NSCLC. This approval marks a significant milestone for Hansoh Pharmaceutical as it expands its presence in the UK market with its first innovative third-generation EGFR-TKI drug developed in China.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investm","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250604:nNDL72BkFW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03692","BK1589","BK1191","BK1583"],"gpt_icon":0},{"id":"2540038637","title":"Hansoh Pharmaceutical - Aumolertinib Mesilate Tablets Was Approved by Mhra for Marketing","url":"https://stock-news.laohu8.com/highlight/detail?id=2540038637","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540038637?lang=en_us&edition=fundamental","pubTime":"2025-06-04 12:06","pubTimestamp":1749009993,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250604:nFWN3S702S:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["03692","BK1191","BK1589","BK1583"],"gpt_icon":0},{"id":"2540250770","title":"Legend Biotech Announces Promising Phase 1 Results for LB2102 CAR-T Therapy in Lung Cancer Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2540250770","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540250770?lang=en_us&edition=fundamental","pubTime":"2025-06-03 22:45","pubTimestamp":1748961928,"startTime":"0","endTime":"0","summary":"Legend Biotech Corporation has announced promising interim results from a Phase 1 study of LB2102, a DLL3-targeted CAR-T cell therapy, in patients with lung cancers. The study, presented at a recent conference, involved patients with relapsed or refractory small-cell lung cancer  and large cell neuroendocrine carcinoma  who had received at least one prior line of therapy. The results indicated that LB2102 was well tolerated, with no dose-limiting toxicities observed up to Dose Level 4. The study also showed encouraging signs of dose-dependent efficacy, with clinical responses correlating with CAR-T cell expansion. These findings support continued dose escalation and further clinical evaluation. Legend Biotech is conducting this study in the U.S. under an exclusive global license agreement with Novartis Pharma AG.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250603:nNDLFvntG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01548","BK4585","BK1576","IE00B64PRP62.GBP","IE00BKPKM429.USD","BK4588","BK4112","BK4139","LU2210149790.SGD","BK1583","HK0000320264.USD","LU2095319765.USD","BK1141","IE00BGHQF748.EUR","BK4505","HK0000320223.HKD","HK0000306685.HKD","LU2210150020.SGD","NDAQ","LEGN","IE00B3QW5Z07.USD","HK0000306701.USD"],"gpt_icon":0},{"id":"2540710707","title":"HBM Holdings Ltd. Files Next Day Disclosure Return to HKEX Announcing Repurchase of 100,000 Shares at HKD 9.0667 Each","url":"https://stock-news.laohu8.com/highlight/detail?id=2540710707","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540710707?lang=en_us&edition=fundamental","pubTime":"2025-06-03 20:49","pubTimestamp":1748954942,"startTime":"0","endTime":"0","summary":"HBM Holdings Ltd. has filed a next day disclosure return with the Hong Kong Stock Exchange, revealing that the company repurchased 100,000 shares to hold as treasury shares. The aggregate price paid for the repurchase was HKD 906,670, resulting in a price of HKD 9.0667 per share. The disclosure is pursuant to the company's share repurchase mandate.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. HBM Holdings Ltd. published the original content used to generate this news brief on June 03, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250603:nNDL60RH8b:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02142","BK1583","BK1574","BK1161"],"gpt_icon":0},{"id":"2540779388","title":"JW Cayman Therapeutics Co. Ltd. Held Extraordinary General Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2540779388","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540779388?lang=en_us&edition=fundamental","pubTime":"2025-06-03 19:50","pubTimestamp":1748951410,"startTime":"0","endTime":"0","summary":"JW Cayman Therapeutics Co. Ltd. held an extraordinary general meeting on June 3, 2025. During the meeting, a proposal to approve, ratify, and confirm the License Agreement and its execution, along with the implementation of the transactions contemplated under the agreement, was put forward. This proposal was approved.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. JW Cayman Therapeutics Co. Ltd. published the original content used to generate this news brief on June 03, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250603:nNDL7Wd6pM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","02126","BK1161","BK1583"],"gpt_icon":0},{"id":"2540579773","title":"BRIEF-Xinyi Energy Announces Proposed PRC Listing Of Selected Solar Farm Projects","url":"https://stock-news.laohu8.com/highlight/detail?id=2540579773","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540579773?lang=en_us&edition=fundamental","pubTime":"2025-06-03 18:33","pubTimestamp":1748946788,"startTime":"0","endTime":"0","summary":"BRIEF-Xinyi Energy Announces Proposed PRC Listing Of Selected Solar Farm ProjectsJune 3  - Xinyi Energy Holdings Ltd 3868.HK:PROPOSED PRC LISTING OF SELECTED SOLAR FARM PROJECTS BY WAY OF SOLAR FARM INFRASTRUCTURE REITAPPLICATION MATERIALS FOR PROPOSED PRC LISTING HAVE BEEN SUBMITTED TO NDRCFurther company coverage: 3868.HK ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250603:nFWN3S60DW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1594","BK1554","BK1583","BK1154","03868"],"gpt_icon":0},{"id":"2540977339","title":"Xinyi Energy - Proposed PRC Listing of Selected Solar Farm Projects by Way of Solar Farm Infrastructure REIT","url":"https://stock-news.laohu8.com/highlight/detail?id=2540977339","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540977339?lang=en_us&edition=fundamental","pubTime":"2025-06-03 18:31","pubTimestamp":1748946667,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250603:nFWN3S60DW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1594","BK1154","BK1554","03868","BK1583"],"gpt_icon":0},{"id":"2540773397","title":"Xinyi Energy - Application Materials for Proposed PRC Listing Have Been Submitted to Ndrc","url":"https://stock-news.laohu8.com/highlight/detail?id=2540773397","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540773397?lang=en_us&edition=fundamental","pubTime":"2025-06-03 18:31","pubTimestamp":1748946667,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250603:nFWN3S60DW:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1594","BK1154","BK1583","03868","BK1554"],"gpt_icon":0},{"id":"2540778797","title":"Youzan Technology Ltd. Buys Back 2 Million Units for HKD 180,000","url":"https://stock-news.laohu8.com/highlight/detail?id=2540778797","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540778797?lang=en_us&edition=fundamental","pubTime":"2025-06-03 18:26","pubTimestamp":1748946389,"startTime":"0","endTime":"0","summary":"Youzan Technology Ltd. announced a buyback transaction involving 2,000,000 units, acquired at a total cost of approximately HKD 180,000. The buyback was conducted as part of the company's strategy to manage its equity structure.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Youzan Technology Ltd. published the original content used to generate this news brief on June 03, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250603:nNDLzYVcb:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1590","BK1109","08083","BK1518","BK1516","BK1583"],"gpt_icon":0},{"id":"2540080714","title":"Innovent Biologics Announces Promising Phase 1/2 Results for IBI354 in Advanced Solid Tumors at 2025 ASCO Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2540080714","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540080714?lang=en_us&edition=fundamental","pubTime":"2025-06-03 09:00","pubTimestamp":1748912422,"startTime":"0","endTime":"0","summary":"Innovent Biologics Inc., a leading biopharmaceutical company, has announced updated clinical data for IBI354, a novel anti-HER2 antibody-drug conjugate , during the 2025 American Society of Clinical Oncology  Annual Meeting. The data, derived from a Phase 1/2 clinical study, highlights the promising anti-tumor efficacy and favorable safety profile of IBI354 across various advanced solid tumors, including ovarian and breast cancer. This study included 368 participants and demonstrated no dose-limiting toxicities at doses up to 18mg/kg, with the most common treatment-related adverse events being anemia, nausea, and a decrease in white blood cell count. The incidence of interstitial lung disease was low at 1.9% and limited to grades 1-2. These findings support Innovent's ongoing development of next-generation ADC therapies and further clinical studies are planned, including a Phase 3 study in platinum-resistant ovarian cancer.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250603:nNDL2BQ6zS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1583","01801","LU2488822045.USD","01911","BK1147","LU1969619763.USD","LU2328871848.SGD","BK1161","BK1589"],"gpt_icon":0},{"id":"2540797988","title":"Frontage Holdings Corporation Expands with New State-of-the-Art CRDMO Facility in Exton, PA","url":"https://stock-news.laohu8.com/highlight/detail?id=2540797988","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540797988?lang=en_us&edition=fundamental","pubTime":"2025-06-03 01:23","pubTimestamp":1748885034,"startTime":"0","endTime":"0","summary":"Frontage Laboratories, Inc., part of Frontage Holdings Corporation, has expanded its capabilities with the launch of a new Contract Research, Development, and Manufacturing Organization  facility in Exton, Pennsylvania. This state-of-the-art, 46,300-square-foot Good Manufacturing Practice  facility enhances Frontage's service offerings in drug substance synthesis, DMPK, safety & toxicology studies, bioanalysis, and clinical trial support. The facility features nine GMP suites tailored to diverse manufacturing needs, including high-potent, aseptic, and non-sterile suites, and is equipped to handle a variety of pharmaceutical forms such as injectables, tablets, and nasal preparations. The expansion underscores Frontage's commitment to accelerating pharmaceutical and biotech innovation by providing a comprehensive, one-stop-shop solution for clinical supplies.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to pro","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250602:nNDL13qDBN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0174","300347","BK0028","BK0216","01521","BK1583","BK1576","BK1141","LU1146622755.USD","LU1820825898.SGD","BK0077"],"gpt_icon":0},{"id":"2540719943","title":"Haidilao founder, Ray Dalio, Forrest Li’s wife among ultra-rich splurging on 8-figure Singapore properties","url":"https://stock-news.laohu8.com/highlight/detail?id=2540719943","media":"businesstimes","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540719943?lang=en_us&edition=fundamental","pubTime":"2025-06-02 23:00","pubTimestamp":1748876400,"startTime":"0","endTime":"0","summary":"Secretlab’s boss, Want Want family, Jack Ma’s wife also among super-rich buying into top-tier real estate here","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"bustime_highlight","url":"https://www.businesstimes.com.sg/property/haidilao-founder-ray-dalio-forrest-lis-wife-among-ultra-rich-splurging-8-figure-singapore-properties","rn_cache_url":null,"customStyle":"","selectors":"body","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.businesstimes.com.sg/property/haidilao-founder-ray-dalio-forrest-lis-wife-among-ultra-rich-splurging-8-figure-singapore-properties","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"bustime_highlight","symbols":["BK1591","BK1589","BK1233","BK1604","06862","LU2488822045.USD","BK1583"],"gpt_icon":0},{"id":"2540798981","title":"MicroPort CardioFlow Medtech Unit to Acquire Balance Stake in Medical Device Firm","url":"https://stock-news.laohu8.com/highlight/detail?id=2540798981","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540798981?lang=en_us&edition=fundamental","pubTime":"2025-06-02 20:24","pubTimestamp":1748867084,"startTime":"0","endTime":"0","summary":"A unit of MicroPort CardioFlow Medtech  agreed to purchase the remaining 49% equity stake it does not already own in Shanghai MicroPort CardioAdvent for 170.9 million yuan, a Friday Hong Kong bourse filing said.Shanghai MicroPort CardioFlow Medtech will buy a 35.27% stake from MicroPort Sinica and 13.73% from Shanghai Zuoqing Enterprise Management Consulting Service Centre.Upon completion, it will own 100% of the target company, the filing said.Shanghai MicroPort CardioAdvent is a high-tech medical device firm specializing in left atrial appendage devices.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1583","BK1100","02160","BK1574"],"gpt_icon":0},{"id":"2540807760","title":"Zylox-Tonbridge Announces Share Repurchase of 80,000 Shares for HKD 1,492,250 in HKEX Disclosure Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2540807760","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540807760?lang=en_us&edition=fundamental","pubTime":"2025-06-02 19:37","pubTimestamp":1748864269,"startTime":"0","endTime":"0","summary":"Zylox-Tonbridge Medical Technology Co., Ltd. has filed a next day disclosure return with the Hong Kong Stock Exchange, reporting the repurchase of 160,000 shares. The total aggregate price paid for the repurchase was HKD 1,492,250. The repurchased shares are being held as treasury shares.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zylox-Tonbridge Medical Technology Co .Ltd. published the original content used to generate this news brief on June 02, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250602:nNDL7HnTtV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1583","BK1100","02190","BK1574","BK1587"],"gpt_icon":0},{"id":"2540674367","title":"Hansoh Pharmaceutical Signs $80 Million License Agreement with Regeneron for Drug Development","url":"https://stock-news.laohu8.com/highlight/detail?id=2540674367","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540674367?lang=en_us&edition=fundamental","pubTime":"2025-06-02 19:24","pubTimestamp":1748863469,"startTime":"0","endTime":"0","summary":"Hansoh Pharmaceutical Group Company Limited has announced a significant licensing agreement with Regeneron Pharmaceuticals, Inc. The agreement grants Regeneron an exclusive worldwide license, excluding the Chinese Mainland, Hong Kong, and Macau, to develop, manufacture, and commercialize HS-20094, an investigational dual GLP-1/GIP receptor agonist. The licensure will see Hansoh receiving an upfront payment of $80 million, with the potential for up to $1.93 billion in milestone payments tied to the product's development, regulatory approval, and commercialization. Additionally, Hansoh will earn double-digit royalties from potential future product sales. HS-20094 has completed multiple Phase II trials with positive results and is currently undergoing a Phase III clinical trial in China. This collaboration marks a strategic advancement for both companies in the biotechnology sector.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. Wh","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250602:nNDL8DrjnQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2468319806.SGD","LU2237438978.USD","LU0109394709.USD","LU0882574055.USD","LU0889565916.HKD","BK4588","LU2023250504.SGD","LU1974910355.USD","LU0289739699.SGD","BK4139","LU2089984988.USD","LU2362541273.HKD","BK1583","LU1917777945.USD","LU0823416689.USD","LU0114720955.EUR","03692","LU0320765992.SGD","LU0058720904.USD","LU2106854487.HKD","BK4585","LU0823434583.USD","LU2362540622.SGD","LU0053666078.USD","REGN","LU2362541513.USD","LU0823434740.USD","BK1589","BK1191"],"gpt_icon":0},{"id":"2540767822","title":"Hansoh Pharmaceutical - Licensors Will Receive an Upfront Payment of US$80 Mln and Be Eligible to Receive up to US$1.93 Bln in Milestone Payments","url":"https://stock-news.laohu8.com/highlight/detail?id=2540767822","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540767822?lang=en_us&edition=fundamental","pubTime":"2025-06-02 19:07","pubTimestamp":1748862428,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250602:nFWN3S3022:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1583","BK1589","03692","BK1191"],"gpt_icon":0}],"pageSize":20,"totalPage":6,"pageCount":2,"totalSize":109,"code":"91000000","status":"200"}]}}